Immunomedics (IMMU) – FDA
-
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
-
UPDATE: Immunomedics (IMMU) granted orphan drug status for treatment of malignant glioma
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to IMMU Stock Lookup